Related Experiment Video
Updated: May 6, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia
Prashant R Tembhare1, Gerald Marti, Adrian Wiestner
1Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892; stetler@mail.nih.gov.
Objectives:
Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstay or in preclinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy.
Methods:
Using the flow cytometric Quantibrite method (BD Biosciences, San Jose, CA) to determine antibodies bound per cell, we quantified the levels of surface expression of CD20, CD22, CD25, and CD52 in CLL cells from 28 untreated patients.
Results:
The CLL cells in all cases expressed CD20, CD22, and CD52 but 4 (14%) cases were negative for CD25. Although the ranking of levels of expression from highest to lowest was CD52, CD20, CD22, and CD25, the level of antigen expression on any specific case could not be accurately predicted.
Conclusions:
Quantification of antigens might be useful in evaluating new antigens to target for therapy and may provide a systematic approach to selecting individualized therapy in CLL.
Insights
Quantifying surface antigens like CD20, CD52, and CD22 on chronic lymphocytic leukemia (CLL) cells is crucial. This helps in predicting response to monoclonal antibody therapy and personalizing treatment strategies for CLL patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Monoclonal antibody therapies targeting CD20, CD52, CD22, and CD25 are vital for chronic lymphocytic leukemia (CLL).
- Surface antigen expression levels on CLL cells may influence treatment efficacy.
Purpose of the Study:
- To quantify the surface expression levels of CD20, CD22, CD25, and CD52 on CLL cells from untreated patients.
- To assess the variability of antigen expression and its potential impact on therapy selection.
Main Methods:
- Utilized flow cytometry with the Quantibrite method to determine antibody binding per cell.
- Analyzed CLL cells from 28 treatment-naive patients for CD20, CD22, CD25, and CD52 expression.
Main Results:
- All CLL samples expressed CD20, CD22, and CD52; however, 14% were negative for CD25.
- The general order of antigen expression from highest to lowest was CD52 > CD20 > CD22 > CD25.
- Individual antigen expression levels varied significantly and could not be reliably predicted.
Conclusions:
- Quantifying antigen expression provides a systematic approach for individualized CLL therapy.
- This method aids in evaluating novel therapeutic targets and optimizing treatment selection for CLL.
